ReviewBiomedicines2024
Menopause-Associated Depression: Impact of Oxidative Stress and Neuroinflammation on the Central Nervous System-A Review.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Antidepressant effects and therapeutic potential of naringenin: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- A meta-analysis on the incidence rate of depression in Chinese menopausal women.BMC psychiatry · 2025Pooled it
- Effect of acupuncture on menopausal depressive disorder and serum hormone levels: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Therapeutic efficacy of botanicals in psychological disorders in menopausal women: a systematic and scoping review.Frontiers in pharmacology · 2025Pooled it
- Association between atherogenic index of plasma and depression risk: a meta-analysis.Frontiers in psychiatry · 2025Pooled it
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Depression, Anxiety and Stress Among Women Treated Due to Infertility.Journal of clinical medicine · 2026Article
- Neuroinflammatory Mechanisms in Depression: From Biomarkers to Anti-Inflammatory Therapy.Brain sciences · 2026Review
- Hepatic Gluconeogenesis and the Antidepressant Effects of Exercise: A Narrative Review.Metabolites · 2026Review
- C/EBPβ dictates postmenopausal FSHβ transcription and blockade of AEP/C/EBPβ pathway alleviates osteoporosis.Bone research · 2026Article
- Article
- Research advances on estrogen deficiency leading to depression.Translational neuroscience · 2026Review
- The Role and Mechanism of Estrogen in Perimenopausal Depression.Current neuropharmacology · 2026Review
- Mitochondrial dysfunction in perimenopausal mood disorders: From hormonal shifts to neuroenergetic failure (Review).International journal of molecular medicine · 2025Review
- Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation.Cells · 2025Review
- Neurokinin Antagonists to Treat Vasomotor Symptoms-Possible Implications for Long-Term Health and Disease.Journal of clinical medicine · 2025Article
- Mechanism of Microbiota-Gut-Brain in Perimenopausal Depression: An Inflammatory Perspective.Expert reviews in molecular medicine · 2025Review
- Optimizing perimenopausal mental health by integrating precision biomarkers, digital health interventions, and psychosocial care.World journal of psychiatry · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Perimenopausal depression, occurring shortly before or after menopause, is characterized by symptoms such as emotional depression, anxiety, and stress, often accompanied by endocrine dysfunction, particularly hypogonadism and senescence. Current treatments for perimenopausal depression primarily provide symptomatic relief but often come with undesirable side effects. The development of agents targeting the specific pathologies of perimenopausal depression has been relatively slow. The erratic fluctuations in estrogen and progesterone levels during the perimenopausal stage expose women to the risk of developing perimenopausal-associated depression. These hormonal changes trigger the production of proinflammatory mediators and induce oxidative stress, leading to progressive neuronal damage. This review serves as a comprehensive overview of the underlying mechanisms contributing to perimenopausal depression. It aims to shed light on the complex relationship between perimenopausal hormones, neurotransmitters, brain-derived neurotrophic factors, chronic inflammation, oxidative stress, and perimenopausal depression. By summarizing the intricate interplay between hormonal fluctuations, neurotransmitter activity, brain-derived neurotrophic factors, chronic inflammation, oxidative stress, and perimenopausal depression, this review aims to stimulate further research in this field. The hope is that an increased understanding of these mechanisms will pave the way for the development of more effective therapeutic targets, ultimately reducing the risk of depression during the menopausal stage for the betterment of psychological wellbeing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.